CSAHi study-2: validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes …
Y Nozaki, Y Honda, H Watanabe, S Saiki… - Regulatory Toxicology …, 2017 - Elsevier
With the aim of reconsidering ICH S7B and E14 guidelines, a new in vitro assay system has
been subjected to worldwide validation to establish a better prediction platform for potential …
been subjected to worldwide validation to establish a better prediction platform for potential …
CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes …
Y Nozaki, Y Honda, H Watanabe, S Saiki… - Regulatory Toxicology …, 2016 - Elsevier
In vitro screening of hERG channels are recommended under ICH S7B guidelines to predict
drug-induced QT prolongation and Torsade de Pointes (TdP), whereas proarrhythmia is …
drug-induced QT prolongation and Torsade de Pointes (TdP), whereas proarrhythmia is …
CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia …
T Kitaguchi, Y Moriyama, T Taniguchi, A Ojima… - … of pharmacological and …, 2016 - Elsevier
Introduction Drug-induced QT prolongation is a major safety issue during drug development
because it may lead to lethal ventricular arrhythmias. In this study, we evaluated the utility of …
because it may lead to lethal ventricular arrhythmias. In this study, we evaluated the utility of …
Mechanistic model‐informed proarrhythmic risk assessment of drugs: review of the “CiPA” initiative and design of a prospective clinical validation study
The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative is developing and
validating a mechanistic‐based assessment of the proarrhythmic risk of drugs. CiPA …
validating a mechanistic‐based assessment of the proarrhythmic risk of drugs. CiPA …
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model
L Guo, L Coyle, RMC Abrams, R Kemper… - toxicological …, 2013 - academic.oup.com
Human induced pluripotent stem cell–derived cardiomyocytes (hiPS-CMs) are capable of
detecting drug-induced clinical arrhythmia, Torsade de Pointes (TdP), and QT prolongation …
detecting drug-induced clinical arrhythmia, Torsade de Pointes (TdP), and QT prolongation …
CSAHi study: detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human …
T Kitaguchi, Y Moriyama, T Taniguchi, S Maeda… - … of pharmacological and …, 2017 - Elsevier
Introduction The use of multi-electrode arrays (MEA) in combination with human induced
pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provides a promising method to …
pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provides a promising method to …
Electrophysiological characteristics of human iPSC-derived cardiomyocytes for the assessment of drug-induced proarrhythmic potential
W Yamamoto, K Asakura, H Ando, T Taniguchi… - PloS one, 2016 - journals.plos.org
The aims of this study were to (1) characterize basic electrophysiological elements of human
induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) that correspond to …
induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) that correspond to …
Comprehensive translational assessment of human-induced pluripotent stem cell derived cardiomyocytes for evaluating drug-induced arrhythmias
Induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) hold promise for
assessment of drug-induced arrhythmias and are being considered for use under the …
assessment of drug-induced arrhythmias and are being considered for use under the …
Cardiotoxicity assessment of drugs using human iPS cell-derived cardiomyocytes: Toward proarrhythmic risk and cardio-oncology
A Satsuka, Y Kanda - Current pharmaceutical biotechnology, 2020 - ingentaconnect.com
Growing evidence suggests that Human Induced Pluripotent Stem Cell-Derived
Cardiomyocytes (hiPSC-CMs) can be used as a new human cell-based platform to assess …
Cardiomyocytes (hiPSC-CMs) can be used as a new human cell-based platform to assess …
[HTML][HTML] Development of torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS Cardiac Safety Assessment …
Y Kanda, D Yamazaki, T Osada, T Yoshinaga… - Journal of …, 2018 - Elsevier
Cardiac safety assessment is challenging because a better understanding of torsadogenic
mechanisms beyond hERG blockade and QT interval prolongation is necessary for patient …
mechanisms beyond hERG blockade and QT interval prolongation is necessary for patient …